Share ChrysCapital has completed the acquisition of a 70.68% controlling stake in Novartis India Limited (NIL) for ₹1,376.8 crore, marking the private equity firm’s first majority-controlled investment in India’s pharmaceutical sector. The landmark transaction signals a new chapter for the company as it transitions from being part of Novartis AG to an independently managed branded generics business focused on the Indian market. Following the acquisition, ChrysCapital has announced a refreshed leadership team to steer the company’s future growth. Dr. Vikas Gupta has been appointed as Managing Director and Chief Executive Officer, while Ramesh Ramadurai has taken over as Chairperson. The Board has also welcomed Suchita Sharma and Shashank Sinha as Independent Directors, strengthening governance and strategic oversight for the company’s transformation journey. Dr. Vikas Gupta brings decades of experience in India’s pharmaceutical industry, having held leadership roles at Ranbaxy, Glenmark, Cipla, and Alkem Laboratories. With deep expertise in branded generics, commercial strategy, and business expansion, he will lead the company’s next phase of growth as ChrysCapital aims to build a stronger domestic pharmaceutical platform. As part of the transition, Novartis India plans to adopt a new corporate identity and operate independently following Novartis AG’s exit as promoter. Backed by ChrysCapital’s healthcare investment expertise and strategic resources, the company intends to strengthen its portfolio across key therapeutic segments, accelerate growth in the branded generics market, and expand its presence in India’s evolving healthcare landscape. Post navigation The Standard India Strengthens Leadership with New HR, Talent Acquisition & Technology Appointments Honda Cars India Appoints Toshiyuki Yanagisawa as President & CEO
